Efficacy and safety of rivaroxaban in cerebral venous thrombosis: insights from a prospective cohort study.

Rivaroxaban, as a novel oral anticoagulant agent, emerged in thrombosis management. This study aimed to compare the efficacy and safety of once-daily rivaroxaban versus dose-adjusted warfarin for cerebral venous thrombosis treatment in a real-world clinical setting. This is a prospective cohort study based on the real-world clinical data analysis of the patients with imaging-confirmed CVT enrolled from August 2016 through January 2020 and their outcomes were followed up. Patients were grouped according to their treatment strategies: rivaroxaban (15-20 mg daily) or warfarin (dosage-adjusted according to international normalized ratio), which were matched 1:2 on the propensity score. The primary efficacy outcome was recanalization assessed by magnetic resonance venography. Thrombus burden, CVT recurrence and modified Rankin Scale (mRS) were also compared. The safety outcome was major bleeding. Baseline characteristics were well balanced between the 33 patients in rivaroxaban group and 49 in warfarin group after propensity score matching. During 6-month (median) follow-up, 29 patients (87.9%) in rivaroxaban group and 38 patients (77.6%) in warfarin group obtained recanalization (OR, 1.44; 95% CI 0.63-3.30). The thrombus reduction at the 6-month follow-up did not reach statistical difference (p = 0.118). No CVT recurrence was observed in both groups. All patients in rivaroxaban group obtained favorable functional outcomes (mRS = 0-2), whereas in warfarin group, 1 patient remained physically disable (mRS = 3) at the follow-up. No major bleeding events occurred in two groups. Rivaroxaban might have the same or stronger efficacy in facilitating CVT recanalization and preventing CVT recurrence with a lower incidence of bleeding than that of warfarin in Chinese population.

Pan L ，Wang M ，Zhou D ，Ding Y ，Ji X ，Meng R ... -  《-》

Safety and Efficacy of Dabigatran Etexilate vs Dose-Adjusted Warfarin in Patients With Cerebral Venous Thrombosis: A Randomized Clinical Trial.

Ferro JM ，Coutinho JM ，Dentali F ，Kobayashi A ，Alasheev A ，Canhão P ，Karpov D ，Nagel S ，Posthuma L ，Roriz JM ，Caria J ，Frässdorf M ，Huisman H ，Reilly P ，Diener HC ，RE-SPECT CVT Study Group ... -  《-》

Rivaroxaban for the treatment of cerebral venous thrombosis.

Esmaeili S ，Abolmaali M ，Aarabi S ，Motamed MR ，Chaibakhsh S ，Joghataei MT ，Mojtahed M ，Mirzaasgari Z ... -  《BMC Neurology》

Direct Oral Anticoagulants Versus Warfarin in the Treatment of Cerebral Venous Thrombosis (ACTION-CVT): A Multicenter International Study.

Yaghi S ，Shu L ，Bakradze E ，Salehi Omran S ，Giles JA ，Amar JY ，Henninger N ，Elnazeir M ，Liberman AL ，Moncrieffe K ，Lu J ，Sharma R ，Cheng Y ，Zubair AS ，Simpkins AN ，Li GT ，Kung JC ，Perez D ，Heldner M ，Scutelnic A ，Seiffge D ，Siepen B ，Rothstein A ，Khazaal O ，Do D ，Kasab SA ，Rahman LA ，Mistry EA ，Kerrigan D ，Lafever H ，Nguyen TN ，Klein P ，Aparicio H ，Frontera J ，Kuohn L ，Agarwal S ，Stretz C ，Kala N ，El Jamal S ，Chang A ，Cutting S ，Xiao H ，de Havenon A ，Muddasani V ，Wu T ，Wilson D ，Nouh A ，Asad SD ，Qureshi A ，Moore J ，Khatri P ，Aziz Y ，Casteigne B ，Khan M ，Cheng Y ，Mac Grory B ，Weiss M ，Ryan D ，Vedovati MC ，Paciaroni M ，Siegler JE ，Kamen S ，Yu S ，Leon Guerrero CR ，Atallah E ，De Marchis GM ，Brehm A ，Dittrich T ，Psychogios M ，Alvarado-Dyer R ，Kass-Hout T ，Prabhakaran S ，Honda T ，Liebeskind DS ，Furie K ... -  《-》

Study of Rivaroxaban for Cerebral Venous Thrombosis: A Randomized Controlled Feasibility Trial Comparing Anticoagulation With Rivaroxaban to Standard-of-Care in Symptomatic Cerebral Venous Thrombosis.

Field TS ，Dizonno V ，Almekhlafi MA ，Bala F ，Alhabli I ，Wong H ，Norena M ，Villaluna MK ，King-Azote P ，Ratnaweera N ，Mancini S ，Van Gaal SC ，Wilson LK ，Graham BR ，Sposato LA ，Blacquiere D ，Dewar BM ，Boulos MI ，Buck BH ，Odier C ，Perera KS ，Pikula A ，Tkach A ，Medvedev G ，Canfield C ，Mortenson WB ，Nadeau JO ，Alshimemeri S ，Benavente OR ，Demchuk AM ，Dowlatshahi D ，Lanthier S ，Lee AYY ，Mandzia J ，Suryanarayan D ，Weitz JI ，Hill MD ，SECRET Investigators ... -  《-》